Patents by Inventor Carlos Lopez-Otin

Carlos Lopez-Otin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9072757
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: July 7, 2015
    Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (AFM), ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE, UNIVERSIDAD DE OVIEDO
    Inventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
  • Publication number: 20150105352
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Nicolas LEVY, Pierre CAU, Carlos LOPEZ-OTIN
  • Publication number: 20130281408
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 24, 2013
    Inventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
  • Patent number: 8518914
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: August 27, 2013
    Assignees: Universite de la Mediterranee AIX-Marseille II, Association Francaise Contre les Myophathies (AFM), Assistance Publique Hopitaux de Marseille, Universidad de Oviedo
    Inventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
  • Publication number: 20100120720
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
    Type: Application
    Filed: July 5, 2007
    Publication date: May 13, 2010
    Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MAR SEILLE II
    Inventors: Nicolas Levy, Pierre Cau, Carlos Lopez-Otin
  • Patent number: 6800473
    Abstract: Novel proteins which belong to the papain family and are cysteine proteinase enzymes (the cysteine proteinase enzymes are expected to be involved in the turnover of intracellular proteins, antigen presentation, prohormone activation, bone remodeling, etc. and to play important roles in a variety of pathological conditions such as Alzheimer's disease, pulmonary emphysema, rheumatoid arthritis, muscular dystrophy, osteoporosis, neurodegenerative disease, and cancer invasion and metastasis), together with genes encoding the proteins and antibodies against the proteins, can be conveniently used in elucidating the function of a cysteine proteinase involved in various diseases and disorders, especially cancers, thereby not only disclosing critical mechanism leading to such diseases and disorders but also researching and developing therapy and therapeutic drugs thereagainst.
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: October 5, 2004
    Assignees: Daiichi Fine Chemical Co., Ltd., Universidad de Oviedo
    Inventors: Inigo Santamaría, Gloria Velasco, Maite Cazorla, Antonio Fueyo, Elías Campo, Carlos López-Otín
  • Publication number: 20030143692
    Abstract: Compositions and methods are provided for identifying and designing modulators of integrin-mediated cell-cell interactions through altering the interaction of ADAM 23 with &agr;v&bgr;3 integrin. Compositions and-methods are also provided for modulating integrin-mediated cell-cell interactions such as those involved in angiogenesis, induction of active metalloproteinases, tumor progression and neural tissue growth.
    Type: Application
    Filed: February 5, 2003
    Publication date: July 31, 2003
    Inventors: Carlos Lopez-Otin, Jose Maria Perez Freije, Santiago Cal Miguel, Jose Manuel Lopez Garcia, Albert Bernard Bianchi, Pamela Trail
  • Publication number: 20020001840
    Abstract: Compositions and methods are provided for identifying and designing modulators of integrin-mediated cell-cell interactions through altering the interaction of ADAM 23 with &agr;v&bgr;3 integrin. Compositions and methods are also provided for modulating integrin-mediated cell-cell interactions such as those involved in angiogenesis, induction of active metalloproteinases, tumor progression and neural tissue growth.
    Type: Application
    Filed: April 2, 2001
    Publication date: January 3, 2002
    Inventors: Carlos Lopez-Otin, Jose Maria Perez Freije, Santiago Cal Miguel, Jose Manuel Lopez Garcia, Albert Bernard Bianchi, Pamela Trail